Key Points An analyst downgraded his recommendation on the Danish pharmaceutical's equity. He changed it from the equivalent of hold to buy. 10 stocks we like better than Novo Nordisk › Drug tariffs, tough competition, and a fresh analyst recommendation downgrade were the burdens pulling down Novo Nordisk (NYSE: NVO) stock on Monday. In some respects, then, it was surprising that the company's shares didn't do worse than the 0.2% slump they were hit with across that trading session. Meanwhile, the ...